Table 1.

Anti‐CD19 CAR T‐cell therapies approved or under investigation in relapsed/refractory large B‐cell lymphoma

Therapy	Axicabtagene ciloleucel(Yescarta) [22]	Tisagenlecleucel(Kymriah) [26]	Lisocabtagene ciloleucel [29]
Patient population	Approved for the treatment of adult patients with relapsed or refractory large B‐cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified, primary mediastinal large B‐cell lymphoma, high‐grade B‐cell lymphoma, and DLBCL arising from follicular lymphoma	Approved for the treatment of adult patients with relapsed or refractory large B‐cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified, high‐grade B‐cell lymphoma, and DLBCL arising from follicular lymphoma	Under investigation in patients with DLBCL after two or more lines of therapy, including DLBCL not otherwise specified (de novo or transformed follicular lymphoma) and high‐grade B‐cell lymphoma (double‐/triple‐hit)
CAR	Anti‐CD19 scFV, CD28 costimulatory domain, CD3ζ activation domain	Anti‐CD19 scFV, 4‐1BB costimulatory domain, CD3ζ activation domain	Anti‐CD19 scFV, 4‐1BB costimulatory domain, CD3ζ activation domain; manufactured in a 1:1 ratio of CD4:CD8 T cells
Pivotal trial	ZUMA‐1 [12, 18] (NCT02348216)	JULIET 28 (NCT02445248)	TRANSCEND NHL 001 [29] (NCT02631044)

Abbreviations: CAR, chimeric antigen receptor; DLBCL, diffuse large B‐cell lymphoma; scFV, single‐chain variable fragment.